|[September 06, 2013]
Medivir: The Collaboration with Daewoong Pharmaceutical for the Development of the Hepatitis B Compound, MIV-210 Has Been Discontinued
STOCKHOLM --(Business Wire)--
Medivir AB (STO:MVIR-B) today announced that it has discontinued the
development of its hepatitis B compound MIV-210 based on a joint
decision with Daewoong Pharmaceutical Co. Ltd., (South Korea).
Under the terms of this collaboration agreement Daewoong has been
responsible for the R&D work. MIV-210 has a demonstrably competitive
antiviral activity but, like other drugs of this class, does not
completely eradicate HBV. The commercial environment for HBV drugs, with
the current standard of care approaching generic status, requires a
robust cure profile. To achieve this cure profile would require
combination with other drugs with different and new mechanisms.
"In light of the characteristics MIV-210 could offer for the treatment
of Hepatitis B, we have together with our partner Daewoong decided to
abando the development activities with MIV-210", said Maris Hartmanis,
CEO, Medivir AB.
Medivir is an emerging research-based pharmaceutical company focused on
infectious diseases. Medivir has world class expertise in polymerase and
protease drug targets and drug development which has resulted in a
strong infectious disease R&D portfolio. The Company's key pipeline
asset is simeprevir, a novel protease inhibitor in late phase III
clinical development for hepatitis C that is being developed in
collaboration with Janssen R&D Ireland. Medivir has also a broad product
portfolio with prescription pharmaceuticals in the Nordics.
For more information about Medivir AB, please visit the Company's
Medivir is a collaborative and agile pharmaceutical company with an R&D
focus on infectious diseases and a leading position in hepatitis C. We
are passionate and uncompromising in our mission to develop and
commercialize innovative pharmaceuticals that improve people's health
and quality of life.
This information was brought to you by Cision http://news.cision.com
[ Back To Technology News's Homepage ]